BridgeBio readies US launch of BBP-418 for LGMD2I/R9 ahead of Nov 27 FDA decision
- The FDA is due to rule on BridgeBio's oral BBP-418 for limb-girdle muscular dystrophy type 2I/R9 by Nov 27 under priority review, with no advisory committee planned; it would be the first approved therapy for the condition.
- The Phase 3 FORTIFY study in 112 patients met its interim biomarker endpoint (glycosylated alpha-dystroglycan) and secondary endpoints including lower serum CK.
- The company already has field teams in place, is targeting about 150 MDA centers and has identified over 500 prospective US patients; pricing is undisclosed, and genetic testing is expected on the label.
💡 Points Based on public reports
The approval hinges on a biomarker: glycosylated alpha-dystroglycan was the interim primary endpoint, so the label will show how much clinical weight FDA gives it versus CK and function data. Commercially, 500-plus identified patients across roughly 150 centers is a small, tightly mapped pool, which makes price and the genetic-testing requirement the swing factors.
BridgeBio gears up for rare muscular dystrophy launch with FDA approval in sight ↗